Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Phyllis Cantor Center for Research in Nursing and Patient Care Services, Dana Farber Cancer Institute, Boston, MA, USA.
Pain Physician. 2021 Mar;24(2):E191-E201.
Clinicians frequently order urine drug testing (UDT) for patients on chronic opioid therapy (COT), yet often have difficulty interpreting test results accurately.
To evaluate the implementation and effectiveness of a laboratory-generated urine toxicology interpretation service for clinicians prescribing COT.
Type II hybrid-convergent mixed methods design (implementation) and pre-post prospective cohort study with matched controls (effectiveness).
Four ambulatory sites (2 primary care, 1 pain management, 1 palliative care) within 2 US academic medical institutions.
Interpretative reports were generated by the clinical chemistry laboratory and were provided to UDT ordering providers via inbox message in the electronic health record (EHR). The Partners Institutional Review Board approved this study.Participants were primary care, pain management, and palliative care clinicians who ordered liquid chromatography-mass spectrometry UDT for COT patients in clinic. Intervention was a laboratory-generated interpretation service that provided an individualized interpretive report of UDT results based on the patient's prescribed medications and toxicology metabolites for clinicians who received the intervention (n = 8) versus matched controls (n = 18).Implementation results included focus group and survey feedback on the interpretation service's usability and its impact on workflow, clinical decision making, clinician-patient relationships, and interdisciplinary teamwork. Effectiveness outcomes included UDT interpretation concordance between the clinician and laboratory, documentation frequency of UDT results interpretation and communication of results to patients, and clinician prescribing behavior at follow-up.
Among the 8 intervention clinicians (median age 58 [IQR 16.5] years; 2 women [25%]) on a Likert scale from 1 ("strongly disagree") to 5 ("strongly agree"), 7 clinicians reported at 6 months postintervention that the interpretation service was easy to use (mean 5 [standard deviation {SD}, 0]); improved results comprehension (mean 5 [SD, 0]); and helped them interpret results more accurately (mean 5 [SD, 0]), quickly (mean 4.67 [SD, 0.52]), and confidently (mean 4.83 [SD, 0.41]). Although there were no statistically significant differences in outcomes between cohorts, clinician-laboratory interpretation concordance trended toward improvement (intervention 22/32 [68.8%] to 29/33 [87.9%] vs. control 21/25 [84%] to 23/30 [76.7%], P = 0.07) among cases with documented interpretations.
This study has a low sample size and was conducted at 2 large academic medical institutions and may not be generalizable to community settings.
Interpretations were well received by clinicians but did not significantly improve laboratory-clinician interpretation concordance, interpretation documentation frequency, or opioid-prescribing behavior.
临床医生经常为接受慢性阿片类药物治疗(COT)的患者开具尿液药物检测(UDT),但往往难以准确解读检测结果。
评估实验室生成的尿液毒理学解释服务在为开具 COT 处方的临床医生中的实施情况和效果。
实施部分采用 II 型混合收敛混合方法设计,效果评估部分采用前瞻性队列研究(实施前-实施后),并设有匹配对照组。
在美国 2 所学术医学机构的 4 个门诊点(2 个初级保健、1 个疼痛管理、1 个姑息治疗)。
临床化学实验室生成解释报告,并通过电子健康记录(EHR)中的收件箱消息提供给 UDT 订单提供者。合作伙伴机构审查委员会批准了这项研究。参与者为在诊所为 COT 患者开具液体色谱-质谱 UDT 的初级保健、疼痛管理和姑息治疗临床医生。干预措施是实验室生成的解释服务,根据接受干预的患者(n=8)和匹配对照组(n=18)的处方药物和毒理学代谢物,为患者提供 UDT 结果的个性化解释报告。实施结果包括焦点小组和调查反馈,内容涉及解释服务的可用性及其对工作流程、临床决策、医患关系和跨学科团队合作的影响。效果评估结果包括临床医生和实验室之间 UDT 解释的一致性、UDT 结果解释和向患者传达结果的记录频率,以及临床医生在随访时的处方行为。
在实施后 6 个月,8 名接受干预的临床医生(中位年龄 58 [IQR 16.5] 岁;2 名女性[25%])对解释服务的易用性进行了评估,他们在 1(“非常不同意”)到 5(“非常同意”)的李克特量表上进行了评分,其中 7 名医生表示解释服务易于使用(平均 5 [SD,0]);提高了他们对结果的理解(平均 5 [SD,0]);帮助他们更准确地(平均 5 [SD,0])、快速地(平均 4.67 [SD,0.52])和自信地(平均 4.83 [SD,0.41])解读结果。尽管两个队列之间的结果没有统计学上的显著差异,但临床医生与实验室的解释一致性有改善趋势(干预组为 22/32 [68.8%]到 29/33 [87.9%],而对照组为 21/25 [84%]到 23/30 [76.7%],P=0.07),但仅在有记录解释的情况下。
这项研究的样本量较小,且仅在 2 家大型学术医疗机构进行,可能无法推广到社区环境。
该解释服务得到了临床医生的好评,但并未显著提高实验室-临床医生解释的一致性、解释记录频率或阿片类药物的处方行为。